Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENTABLE: Atorvastatin in Older Adults
NCT04262206Phase 4Recruiting
- Sponsor
- Duke University
- Start
- Sep 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in Dementia, cardiovascular disease (CVD) and Mild Cognitive Impairment (MCI) comparing atorvastatin 40mg with Placebo (2 arms). Primary endpoints: Number of patients without diagnosis of new dementia at 4 years and Number of patients without persistent disability at 4 years. Started Sep 2020; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
Dementiacardiovascular disease (CVD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04262206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262206.